DJIA 17,745.98 -5.41 -0.03%
NASDAQ 5,128.79 17.05 0.33%
S&P 500 2,108.63 0.06 0.00%
market minute promo

547.10 0.83 (0.15%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

REGN $547.10 0.15%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $545.63
Previous Close $546.27
Daily Range $536.02 - $550.25
52-Week Range $310.69 - $569.92
Market Cap $56.5B
P/E Ratio 175.09
Dividend (Yield) $0.00 (0.0%)
Volume 556,314
Average Daily Volume 636,120
Current FY EPS $8.31

Sector

Healthcare

Industry

Drug Makers

Regeneron Pharmaceuticals, Inc. (REGN) Description

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions. Website: http://www.regeneron.com/

News & Commentary Rss Feed

Regeneron Pharmaceuticals and Sanofi Grab a Blockbuster FDA Approval

The FDA has given the nod to the sale of Praluent, the first of a new class of cholesterol lowering medications, and a blockbuster opportunity for the company's.

The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases

Regeneron's Mega-Blockbuster Potential With Praluent: CVS Health Sees It, So Why Don't More Analysts

Regeneron's Mega-Blockbuster Potential With Praluent: CVS Health Sees It, So Why Don't More Analysts?

Sanofi & Regeneron Enter Immuno-Oncology Collaboration - Analyst Blog

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog

Regeneron Shares Rising After Sanofi Collaboration Revealed: Good News For Shareholders?

The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceu

The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases

Struggling Sanofi Sends Cancer SOS to Regeneron and Another Vanity Biotech IPO Launches

US Stock Futures Surge Ahead Of Fed Meeting

Regeneron Pharmaceuticals CEO Boasts Recently Approved Cholesterol-Lowering Drug

Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog

See More REGN News...

REGN's Top Competitors

REGN $547.10 (0.15%)
Current stock: REGN
AMGN $171.69 (0.13%)
Current stock: AMGN
GILD $117.90 (1.89%)
Current stock: GILD
BIIB $317.00 (1.17%)
Current stock: BIIB